H.C. Wainwright has commenced coverage on Galectin Therapeutics (GALT, Financial), issuing a Buy recommendation and setting a price target of $6. The primary focus for Galectin is belapectin, an innovative therapy administered intravenously that inhibits galectin-3, a protein integral to cell functions such as signaling, differentiation, apoptosis, and inflammation. Despite previous challenges faced by the company, the firm is optimistic about Galectin's potential for a rebound. They highlight belapectin’s distinct approach, which targets a molecule of significant clinical importance.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.